Likewise, ibrutinib treatment of CLL patient cells enrolled significant downregulation of peptides associated with BTK as well as off-target kinases JAK2/3, LYN, BLK, and other Tec kinases (Figure 3A,B). The gene discussed is JAK2; the disease is B-cell chronic lymphocytic leukemia.